Why CVM Stock dropped -8.00% Today — RQD Quant Desk Flash

Per the Roarable RQD rating, CVM scores 36 out of 100 (letter grade D-, verdict "Roarable Sell — Vulnerable Balance Sheet & Flow"). The five pillars are: Fundamental Cash Engine 8/20 (ROIC -35%; FCF yield 0%), Whale 13F Flow 3/20 (institutional accumulation and options positioning), Insider Conviction 5/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 10/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet 10/20 (Altman Z 2.5; Piotroski F 3/9; Debt/Equity 0.5). The lowest-scoring pillars are institutional flow and insider conviction, which are the two areas where the source data shows the least supportive positioning. For a prospective investor, the fundamental pillar is the central concern: negative ROIC and a 0% FCF yield mean the reported operating losses are not currently offset by cash generation, so any valuation case depends on future operating change rather than present cash returns. The forensic pillar indicates a balance sheet that is neither distressed by the Altman threshold nor strong by Piotroski standards. Macro sensitivity at Beta 1.0 implies market-level volatility rather than amplified risk. Upside drivers in the source data are principally the catalyst flow and the proprietary liquidity signal; valuation tradeoffs are severe given the $26.4M market capitalization against reported annual losses. This is analytical context, not personalized financial advice.

Per the SEC financials, reported revenue is $0.0M across all three periods, with operating losses narrowing from $-31.5M (FY 2023) to $-24.8M (FY 2025). Margins are 0% on gross, operating, and net bases per the market data, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 3/9, and Debt/Equity is 0.5. Cash and debt balances are not available in source data for any period.

Per the recent news feed, the flow includes several items tied to Multikine clinical data. A Business Wire release reports new Phase 3 Multikine data presented at a World Congress, with pre-surgical biomarkers identifying a subgroup with 73% 5-year survival, and a Yahoo Finance item reports 73.4% five-year survival in a Multikine Phase 3 patient analysis. Investing.com also reports survival data from the Multikine study. A catalyst-tagged item reports the stock jumping 11.98% to $2.71 as buyers pushed toward resistance. Risk watch items include the stock's -6.25% change in the latest market data and its 52-week low of $0.89. Per the Butterfly Supply-Chain Graph, a LIQUIDITY_TAILWIND signal is marked BULLISH with severity 94, a MACRO TAILWIND SCORE of 96/100, and a rolling 5-year Net Liquidity beta of 3.86x (r = -0.18). The signal's own brief reports a True Net Liquidity Index of $5,745.73B and a -0.64% 4-week change, and the proprietary signal should be read as model output rather than confirmed causation.

Per the Butterfly Supply-Chain Graph, supply chain is NONE and there are no butterfly links. Upstream and downstream dependencies are not available in source data. The only cross-asset linkage is the liquidity-beta relationship in the proprietary signal (3.86x Net Liquidity elasticity), which indicates sensitivity to Fed balance-sheet and liquidity conditions rather than to a named supplier or customer. Second-order bottlenecks cannot be identified from the source data.

• What are the company's cash and debt balances, given that these fields are N/A across all reported periods?
• What is the company's revenue model, given that reported revenue is $0.0M in each year?
• Which figure for market capitalization is correct, given the $26.4M market data versus the $0.0B profile entry?
• What is the timing and regulatory status of the Multikine program, which underlies the survival-data catalysts?
• What are the drivers and magnitude of the 3.86x liquidity beta, given the r = -0.18 correlation reported in the proprietary signal?